Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: James P who wrote (2823)	9/20/1999 12:10:00 PM
From: Meisterama	Read Replies (1) \| Respond to of 2887

Gee, lots of buying today for a change. I wonder if it means anything at all?

To: James P who wrote (2823)	10/28/1999 9:52:00 PM
From: James P	Respond to of 2887

News THE WOODLANDS, Texas, Oct. 28 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news), a leading medical device developer and manufacturer of minimally invasive devices for the treatment of cardiovascular disease and proprietary balloon catheters for cardiovascular, urinary and other disorders, today announced that it has engaged THE NIR GROUP, which has offices in New York and Los Angeles, to structure a $10 million financing. The first financing tranche has been received. The Company indicated that it anticipates receipt of additional funding tranches as the revised strategic plan is implemented and specific milestones are completed. In addition, THE NIR GROUP has been retained as American BioMed's investment banker and financial advisor for acquisitions and strategic planning. Steven B. Rash, President and CEO, stated, ''This financing will provide American BioMed, Inc. with sufficient operating capital to enable the Company to expeditiously implement the Company's strategic plan to reposition the company as a developer and marketer of minimally invasive surgical devices. The Company will utilize these capital resources now at our disposal to accelerate development of the Company's core technologies, expand the marketing efforts in the balloon catheter product line, form additional strategic alliances, and grow the Company via synergistic acquisitions of technologies, product lines or companies.'' A source close to THE NIR GROUP stated, ''We believe American BioMed's strategic plan and vision has positioned the Company as an emerging medical device company with significant proprietary technologies and broad patent coverage. We look forward to assisting the Company in meeting its goals and objectives as well as evaluating strategic acquisition opportunities to help maximize shareholder value.'' American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100%-silicone catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath®, an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion.

To: James P who wrote (2823)	11/11/1999 3:46:00 PM
From: James P	Read Replies (2) \| Respond to of 2887

News American BioMed Granted Approval for Marketing and Sale of OmniCath in the European Market THE WOODLANDS, Texas--(BW HealthWire)--Nov. 11, 1999-- Company Receives the CE Mark to Market Its Artherectomy Device in Europe Representing a Target Market in Excess of $500 Million American BioMed., Inc. (OTC Bulletin Board: ABMI), a leading medical device developer and manufacturer of minimally invasive devices for the treatment of cardiovascular disease and proprietary balloon catheters for cardiovascular, urinary and other disorders, today announced that it has received CE Marking for OmniCath(R)(TM), the Company's atherectomy catheter designed to remove artherosclerotic plaque from obstructed blood vessels throughout the body, for marketing and sale. This represents the seventh product for which the Company has received the CE Mark. Obtaining the CE Mark signifies that the Company's product has attained rigorous international standards concerning quality and efficacy. The OmniCath(R) product launch will take place at the November, 1999 Medica Conference in Dusseldorf, Germany one of the premier venues in the world. Steve Rash, President and Chief Executive Officer, stated, "OmniCath(R) is unique from the competition's product in design and technology. With a target market in excess of $500 million, distribution in place and the likelihood that OmniCath(R) will become an "industry-standard" in vascular surgery, this acceptance represents one of the most significant milestones in the Company's history and in its forward momentum." Marshall Kerr, Vice President of Sales and Marketing, concluded, The Company's products have been gaining momentum in the European countries. OmniCath's(R) introduction into this market will strengthen the Company's sales potential in these countries. In addition, the acquiring of the CE Mark allows us to proceed with the registration and clinical trials in Japan. These trials will be used to validate the Omnicath technology for the US market. We will start the product introduction and physician training in the first quarter of 2000." American BioMed, founded in 1984, utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for use in interventional cardiology, endovascular surgery, minimally invasive surgery, and drug delivery therapeutics. The company has over 25 patents and 11 FDA approvals in its product portfolio. American BioMed has 60 distributors and is represented in over 40 countries This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be accompanied by words such as "expect," "anticipate," or "should" that convey the uncertainty of future events or outcomes. These statements are based on assumptions that the Company believes are reasonable; however many important factors could cause the Company's actual results in the future to differ materially from the forward looking statements made herein or in any other documents or oral presentations made by, or on behalf of the Company. Factors which could cause or contribute to such differences include, but are not limited to, the uncertainties associated with governmental regulation, general economic and other market conditions, the results of research and development efforts, the results of pre-clinical and clinical testing, the impact of competitive product development and other risk factors set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties. The Company assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company. CONTACT: DeMonte Associates Cynthia DeMonte, 212-473-3700 (Investor Contact) cdemonte@demonte.com KEYWORD: TEXAS INTERNATIONAL EUROPE